New imaging tracer maps tumors in cancer patients
NCT ID NCT01269593
First seen Jan 17, 2026 · Last updated Apr 28, 2026 · Updated 15 times
Summary
This study uses a tiny amount of a radioactive tracer called 124I-PUH71 to take PET scans of cancer patients. The goal is to see where the tracer goes in the body and how long it stays in the blood. This information will help researchers plan future studies using higher doses of PUH71 as a possible cancer treatment or as a way to detect tumors. The study includes people with non-Hodgkin's lymphoma, myeloma, or other solid tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.